Drugs / Ramatroban
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT05706454 | Nov 2022 → Jul 2024 | COVID-19, pneumonia | KARE Biosciences | Unknown | No outcome recorded |
| Phase 2/3 | NCT00311051 | Apr 2005 → Apr 2007 | asthma | Research Center Borstel | Withdrawn | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ramatroban | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00311051 ↗ |
| Known as | BAY-U-3405 | ChEMBL registry synonym — accepted as the source's own label CHEMBL361812 ↗ |
| Known as | Baynas | ChEMBL registry synonym — accepted as the source's own label CHEMBL361812 ↗ |
| Known as | EN-137774 | ChEMBL registry synonym — accepted as the source's own label CHEMBL361812 ↗ |
| Action | Inhibit | “G protein-coupled receptor 44 antagonist” CHEMBL361812 ↗2“Thromboxane A2 receptor antagonist” CHEMBL361812 ↗ “Thromboxane A2 receptor antagonist” NCT00311051 ↗ |
| Modality | Small molecule | — CHEMBL361812 ↗ |
| Route | Oral | “Route of Administration: Oral” NCT05706454 ↗ |
| Target | PTGDR2 | “G protein-coupled receptor 44 antagonist” CHEMBL361812 ↗ |
| Target | TBXA2R | “Thromboxane A2 receptor antagonist” CHEMBL361812 ↗ |